2/13/2013

Drugmaker Shire is starting Phase III clinical trials on an experimental dermal substitute therapy to treat nonhealing wounds in patients with epidermolysis bullosa. The FDA granted orphan drug status to the therapy and granted it fast-track approval.

Full Story:
Nasdaq.com

Related Summaries